Dynamic Visual Representation of Clinical Efficacy of Ixekizumab in Psoriasis

Abstract

Introduction: Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, is an approved treatment for plaque psoriasis. This study aimed to use animated visualizations as a tool to simplify complex data from ixekizumab clinical trials. Methods: Animated visualizations were developed to show outcomes from ixekizumab clinical trials and a Bayesian network meta-analysis of 11 approved biologics. The visualizations simultaneously highlighted both aggregate scores and the individual progression of patients over the course of treatment. Results: The animations provided key messages and information from the complex data in efficient and scientific ways that were also visually pleasing and simple to understand. The animations highlighted (1) rapid reduction in disease severity from baseline; (2) sustained efficacy of ixekizumab in the treatment of skin and nail psoriasis; (3) side-by-side comparisons of treatment efficacy and clinical improvement across trials; (4) simultaneous visual presentation of individual results with summary response over time; and (5) indirect comparison of relative treatment effects with other biologics based on Bayesian network meta-analysis. Conclusion:The rapid and sustained efficacy of ixekizumab in the treatment of psoriasis was demonstrated using multiple dynamic visualizations with different clinical endpoints. Animated visualizations provided a simpler and more comprehensive understanding of complex data than conventional static figures.

The Current Advancement in Psoriasis

“…Ixekizumab has shown continued effectiveness in the treatment of psoriasis of the skin and nails. Based on comparison studies with comparative therapies, ixekizumab has shown great significance in treating plaque psoriasis [ 33 ]. In the long-term open-label phases of the psoriasis program, brodalumab was administered to every participant who committed suicide [ 34 ].…”

“…Biologics plays an important role in treating this condition [25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42]. Table 1 shows important biologics.…”